SCHEMBL1709526

SCHEMBL1709526

Cc1ccc(SC(C(=O)Nc2ccc(Cl)cn2)c2ccc(Cl)cc2)cc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.51
L3MBTL1 Q9Y468 4/20 0.47
ALDH1A1 P00352 4/20 0.47
HTT P42858 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
TSHR P16473 2/20 0.45
TP53 P04637 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
PTK2 Q05397 1/20 0.45
FFAR2 O15552 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
KDM4E B2RXH2 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL935447 0.99 SMN1; SMN2 (0.50) SMN1; SMN2L3MBTL1ALDH1A1HTTMEN1
SCHEMBL1709594 0.88 L3MBTL1 (0.53) SMN1; SMN2L3MBTL1ALDH1A1HTTMEN1
SCHEMBL933295 0.87 SMN1; SMN2 (0.57) SMN1; SMN2L3MBTL1ALDH1A1HTTMEN1
Hydrochloric Acid SCHEMBL933932 0.87 L3MBTL1 (0.51) SMN1; SMN2L3MBTL1ALDH1A1HTTMEN1
Hydrochloric Acid SCHEMBL1286268 0.86 SMN1; SMN2 (0.56) SMN1; SMN2L3MBTL1ALDH1A1HTTMEN1
SCHEMBL935450 0.83 FFAR2 (0.56) SMN1; SMN2L3MBTL1ALDH1A1HTTMEN1
SCHEMBL1709614 0.83 FFAR2 (0.56) SMN1; SMN2L3MBTL1ALDH1A1HTTMEN1
SCHEMBL934170 0.82 NPSR1 (0.56) SMN1; SMN2L3MBTL1ALDH1A1HTTMEN1
SCHEMBL1709535 0.82 RAB9A (0.49) SMN1; SMN2L3MBTL1ALDH1A1HTTMEN1
Hydrochloric Acid SCHEMBL933845 0.82 FFAR2 (0.55) SMN1; SMN2L3MBTL1ALDH1A1HTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS ALLERGAN, INC. (US) 2012-04-12 US disclosed
WO-2011008475-A1 OPTIONALLY SUBSTITUTED 2-(ARYLMETHYL, ARYLOXY OR ARYLTHIO) -N- PYRIDIN-2 -YL-ARYL ACETAMIDE OR 2, 2-BIS (ARYL) -N-PYRIDIN-2-YL ACETAMIDE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF EYE DISEASES ALLERGAN, INC. (US) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS S1PR3, S1PR5, S1PR1 SMN1; SMN2 3896/4885L3MBTL1 4123/4885ALDH1A1 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.